The Technical AnalystExchange: HEL Sector: Healthcare Industry: Biotechnology
Herantis Pharma Oyj Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.71% €1.390
America/New_York / 2 mai 2024 @ 10:39
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 28.02 mill |
| EPS: | 0.0200 |
| P/E: | 69.50 |
| Earnings Date: | Mar 06, 2024 |
| SharesOutstanding: | 20.16 mill |
| Avg Daily Volume: | 0.0101 mill |
| RATING 2024-05-02 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | ||||
| Asset | n/a | n/a | ||||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 5.00x |
| Company: PE 69.50 | sector: PE 13.91 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 69.50 | industry: PE -1.961 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
€0.318 (-77.12%) €-1.072 |
| Date: 2024-05-02 |
| Expected Trading Range (DAY) |
|---|
|
€ 1.337 - 1.443 ( +/- 3.81%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €1.390 (-0.71% ) |
| Volume | 0.0021 mill |
| Avg. Vol. | 0.0101 mill |
| % of Avg. Vol | 20.67 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HRTIS.HE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
HRTIS.HE
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.